Efficacy of Adjuvant-associated COVID-19 Vaccines Against SARS-CoV-2 Variants of Concern in Randomized Controlled Trials: A Systematic Review and Meta-analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2024 Feb 16

PMID 38363919

Authors

Meng-Qun Cheng

Zhi-Ying Weng

Rong Li

Gao Song

Affiliations

Soon will be listed here.

Abstract

Background: Adjuvants may enhance the efficacy of vaccines. however, the efficacy of adjuvant-associated COVID-19 vaccines (ACVs) remains unclear since the emergence of the COVID-19 pandemic. This study aimed to address this gap by conducting a systematic review and meta-analysis of the efficacy of ACVs against Severe Acute Respiratory Syndrome Coronavirus 2 CoV (SARS-CoV-2) variants of concern (VOC).

Methods: A systematic search was conducted of randomized controlled trials (RCTs) evaluating the vaccine efficacy (VE) of ACVs against VOC (alpha, beta, gamma, delta, or Omicron), up to May 27, 2023. The DerSimonian-Laird random-effects model was used to assess VE with 95% confidence intervals (CI) through meta-analysis. Cochrane Risk of Bias tools were used to assess the risk of bias in RCTs.

Results: Eight RCTs with 113,202 participants were included in the analysis, which incorporated 4 ACVs [Matrix-M (NVX-CoV2373), Alum (BBV152), CpG-1018/Alum (SCB-2019), and AS03 (CoVLP]). The pooled efficacy of full vaccination with ACVs against VOC was 88.0% (95% CI: 83.0-91.5). Full vaccination was effective against Alpha, Beta, Delta, and Gamma variants, with VE values of 93.66% (95% CI: 86.5-100.74), 64.70% (95% CI: 41.87-87.54), 75.95% (95% CI: 67.9-83.99), and 91.26% (95% CI: 84.35-98.17), respectively. Currently, there is a lack of RCT evidence regarding the efficacy of ACVs against the Omicron variant.

Conclusion: In this meta-analysis, it should be that full vaccination with ACVs has high efficacy against Alpha or Gamma variants and moderate efficacy against Beta and Delta variants. Notably, with the exception of the aluminum-adjuvanted vaccine, the other ACVs had moderate to high efficacy against the SARS-CoV-2 variant. This raises concerns about the effectiveness of ACVs booster vaccinations against Omicron.

Citing Articles

Feasibility and Effectiveness of Vaccines for COVID-19: An Umbrella Review.

SeyedAlinaghi S, Pashapouryeganeh A, Dehghani S, Mirzapour P, Abbaspour F, Afroughi F Arch Acad Emerg Med. 2024; 13(1):e6.

PMID: 39318867 PMC: 11417638. DOI: 10.22037/aaem.v12i1.2357.

References

Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V . Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet. 2021; 398(10317):2173-2184. PMC: 8584828. DOI: 10.1016/S0140-6736(21)02000-6. View

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 2011; 3(3):e123-30. PMC: 3090117. View

Heath P, Galiza E, Baxter D, Boffito M, Browne D, Burns F . Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. N Engl J Med. 2021; 385(13):1172-1183. PMC: 8262625. DOI: 10.1056/NEJMoa2107659. View

Veneti L, Berild J, Watle S, Starrfelt J, Greve-Isdahl M, Langlete P . Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022. Int J Infect Dis. 2023; 130:182-188. PMC: 9991321. DOI: 10.1016/j.ijid.2023.03.004. View

Sterne J, Savovic J, Page M, Elbers R, Blencowe N, Boutron I . RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366:l4898. DOI: 10.1136/bmj.l4898. View

Higgins J, Altman D, Gotzsche P, Juni P, Moher D, Oxman A . The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. PMC: 3196245. DOI: 10.1136/bmj.d5928. View

Carabelli A, Peacock T, Thorne L, Harvey W, Hughes J, Peacock S . SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol. 2023; 21(3):162-177. PMC: 9847462. DOI: 10.1038/s41579-022-00841-7. View

Priesemann V, Balling R, Bauer S, Beutels P, Valdez A, Cuschieri S . Towards a European strategy to address the COVID-19 pandemic. Lancet. 2021; 398(10303):838-839. PMC: 8352491. DOI: 10.1016/S0140-6736(21)01808-0. View

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

10.

Grana C, Ghosn L, Evrenoglou T, Jarde A, Minozzi S, Bergman H . Efficacy and safety of COVID-19 vaccines. Cochrane Database Syst Rev. 2022; 12:CD015477. PMC: 9726273. DOI: 10.1002/14651858.CD015477. View

11.

Anez G, Dunkle L, Gay C, Kotloff K, Adelglass J, Essink B . Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial. JAMA Netw Open. 2023; 6(4):e239135. PMC: 10536880. DOI: 10.1001/jamanetworkopen.2023.9135. View

12.

Winokur P, Hegmann T, Keitel W, Bernstein D, Frey S, Bryant C . Safety and Immunogenicity of a monovalent inactivated influenza A/H5N8 virus vaccine given with and without AS03 or MF59 adjuvants in healthy adults. Clin Infect Dis. 2023; . DOI: 10.1093/cid/ciac983. View

13.

Melo Espindola O, Fuller T, de Araujo M, Tort L, Guaraldo L, Calvet G . Reduced ability to neutralize the Omicron variant among adults after infection and complete vaccination with BNT162b2, ChAdOx1, or CoronaVac and heterologous boosting. Sci Rep. 2023; 13(1):7437. PMC: 10165291. DOI: 10.1038/s41598-023-34035-9. View

14.

Czypionka T, Iftekhar E, Prainsack B, Priesemann V, Bauer S, Valdez A . The benefits, costs and feasibility of a low incidence COVID-19 strategy. Lancet Reg Health Eur. 2022; 13:100294. PMC: 8720492. DOI: 10.1016/j.lanepe.2021.100294. View

15.

Shinde V, Cho I, Plested J, Agrawal S, Fiske J, Cai R . Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial. Lancet Infect Dis. 2021; 22(1):73-84. DOI: 10.1016/S1473-3099(21)00192-4. View

16.

Parums D . Editorial: Current Status of Two Adjuvanted Malaria Vaccines and the World Health Organization (WHO) Strategy to Eradicate Malaria by 2030. Med Sci Monit. 2023; 29:e939357. PMC: 9814194. DOI: 10.12659/MSM.939357. View

17.

Krueger T, Gogolewski K, Bodych M, Gambin A, Giordano G, Cuschieri S . Risk assessment of COVID-19 epidemic resurgence in relation to SARS-CoV-2 variants and vaccination passes. Commun Med (Lond). 2022; 2:23. PMC: 9053266. DOI: 10.1038/s43856-022-00084-w. View

18.

Castrodeza-Sanz J, Sanz-Munoz I, Eiros J . Adjuvants for COVID-19 Vaccines. Vaccines (Basel). 2023; 11(5). PMC: 10222622. DOI: 10.3390/vaccines11050902. View

19.

Chang S, Liu H, Wu J, Xiao W, Chen S, Qiu S . Effectiveness of BNT162b2 and mRNA-1273 Vaccines against COVID-19 Infection: A Meta-Analysis of Test-Negative Design Studies. Vaccines (Basel). 2022; 10(3). PMC: 8954872. DOI: 10.3390/vaccines10030469. View

20.

Li M, Wang H, Tian L, Pang Z, Yang Q, Huang T . COVID-19 vaccine development: milestones, lessons and prospects. Signal Transduct Target Ther. 2022; 7(1):146. PMC: 9062866. DOI: 10.1038/s41392-022-00996-y. View